Canopy Growth reported $81.4M in Q2 FY2027 net revenue, up 22%, with international markets cannabis revenue rising 141% to $12.3M. Cannabis segment revenue reached $66.2M, up 30%, while adjusted EBITDA loss improved to $2.9M.
CGC · Canopy Growth Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Canopy Growth deconsolidated Canopy USA effective April 30, 2024 and retains a non-controlling interest in the independently operated company, which holds interests in Acreage, Wana and Jetty.
At its October 23, 2026 annual meeting, Canopy Growth shareholders elected five directors, appointed MNP, and approved a share consolidation at a Board-determined ratio ranging from one post-consolidation share for every five to fifteen outstanding pre-consolidation shares.
Canopy Growth received a Nasdaq notice on October 14, 2026 that its common shares no longer comply with the $1.00 Minimum Bid Price Requirement and has until April 12, 2027 to regain compliance, with a Share Consolidation proposal up for vote at the reconvened Annual Meeting on October 23, 2026.
Canopy Growth Corporation received notice from Nasdaq on October 14, 2026 that it is not in compliance with Nasdaq Listing Rule 5450(a)(1), as its common shares traded below $1.00 for 30 consecutive business days, giving it until April 12, 2027 to regain compliance.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin non-GAAP | 31% | Q2 FY2027 | — |
|
|
|||
| adjusted gross margin for the segment non-GAAP | 29% | Q2 FY2027 | — |
| Adjusted EBITDA non-GAAP | -3.24M | Three months ended June 30 | — |
| Adjusted EBITDA loss non-GAAP | $3.2M | the first quarter of fiscal 2027 filing | — |
| Cannabis segment gross margin percentage | 22% | the three months ended June 30, 2026 filing | — |
| Free cash flow non-GAAP | -25.75M | Three months ended June 30 | — |
GAAP → non-GAAP reconciliationGAAP Net cash used in operating activities -25.01M
-737K Purchases of and deposits on property, plant and equipment
= Free cash flow -25.75M
|
|||
| Gross margin percentage | 27% | the three months ended June 30, 2026 filing | — |
| Storz & Bickel segment gross margin percentage | 48% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGC
this stock
Canopy Growth Corp
|
$237.59M | -50.8% | — | — | 7.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 27
Canopy Growth reported $81.4M in Q2 FY2027 net revenue, up 22%, with international markets cannabis revenue rising 141% to $12.3M. Cannabis segment revenue reached $66.2M, up 30%, while adjusted EBITDA loss improved to $2.9M.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGC | -13.9% | -21.3% | -46.6% | -14.0% | -50.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -16.5% | -20.1% | -47.1% | -13.8% | -61.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.